Back to Explorer

Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues

DraftHuman Foods Program04/03/2024

Description

Under section 413(a)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 350b(a)(2)), the manufacturer or distributor of a new dietary ingredient (NDI) that has not been present in the food supply as an article used for food, or a dietary supplement containing such an NDI, must submit a premarket safety notification to FDA at least 75 days before introducing the product into interstate commerce.

Scope & Applicability

Product Classes

5
Dietary Supplement

Products containing dietary ingredients intended to supplement the diet; The final product category for which the NDI is intended.

Pre-DSHEA dietary ingredient

A dietary ingredient that was marketed in the U.S. before October 15, 1994

Food Additive

Approved substances for direct addition to food

New Dietary Ingredient

A dietary ingredient that was not marketed in the United States before October 15, 1994.; A dietary ingredient not marketed in the U.S. before October 15, 1994; A dietary ingredient that was not marketed in the U.S. before October 15, 1994.; Abbreviated as NDI in the text; Ingredients that may require notification if chemically altered.; Ingredient requiring safety notification before marketing.; defined as an ingredient not marketed in the U.S. before October 15, 1994; Identity Information Abou

Conventional Food

Food marketed for general consumption, distinct from dietary supplements.; Comparison point for intake levels

Stakeholders

5
Manufacturer

Entity responsible for submitting NDINs

Institutional Review Board

Governs top dose in clinical studies

Trained practitioner of traditional medicine

Supervising individual for medicinal products

American Type Culture Collection

internationally recognized third-party repository

Distributor

Entity responsible for submitting NDINs

Regulatory Context

Attributes

10
No Observed Adverse Effect Level

The highest dose at which no adverse effects are observed (NOAEL).; identified by the subchronic oral study to assess safety

Formulation

A formula that lists the identity and quantity of each dietary ingredient and other ingredients

Subchronic

Repeated exposure for 1 to 3 months.

Chronic

Exposure for more than 3 months or toxicology studies of at least 1 year.

Safety factor

NOAEL is divided by a safety factor to derive the ADI; Uncertainty factors used to account for differences between animals and humans and sensitivity among humans.; A multiplier used to account for uncertainty in safety data extrapolation

Margin of safety

state the basis for the margin of safety for the NDI; Calculated by dividing the NOAEL by the estimated daily intake (EDI).; A measure of how close the estimated daily intake is to the NOAEL

ADI

acceptable daily intake (ADI) for the NDI

Antibiotic resistance

document resistance to any clinically relevant antibiotics

NOAEL

No-observed adverse effect level for histological changes

Maximum Tolerated Dose

Highest dose in animal studies to detect toxicity; identified by subchronic oral toxicity studies

Identified Hazards

Hazards

9
Genotoxic

A substance that can cause genetic mutations or cancer.

Genetic toxicity hazard

Identified by positive findings in standard tests

Human Pathogens

species known to contain human pathogens; identify pathogens phylogenetically related to the fermentation microorganism; identify any human pathogens phylogenetically related to the microbial NDI

Toxins

identify toxins or classes of toxins in related plants; identify toxins known to be present in the same species; identify any toxins known to be present in the same species

Mold contamination

establish a specification to limit mold contamination of a component

Contaminants

identity and level of any impurities and contaminants

Impurities

identity and level of any impurities and contaminants

Contaminant

substances like Salmonella or lead found in food supply

Cardiotoxic activity

Safety concern associated with certain botanical extracts.

Related CFR Sections (7)

Related Warning Letters (10)

  • Clinical Investigator

    Shirish M. Gadgeel, M.D.

    2025-09-09
  • Clinical Investigator

    Mark J. Savant, M.D

    2025-07-15
  • Bioresearch Monitoring Program/Institutional Review Board (IRB)

    United Health Products, Inc.

    2025-05-20
  • Clinical Investigator

    Americo F. Padilla, M.D.

    2025-03-25
  • CGMP/Dietary Supplement/Adulterated

    Western Innovations, Inc.

    2025-01-21
  • Institutional Review Board (IRB)

    Armstrong County Memorial Hospital

    2024-11-05
  • Clinical Investigator

    Namita A. Goyal, M.D.

    2024-10-22
  • Institutional Review Board (IRB)

    Louisiana State University Health Science Center IRB

    2024-10-08
  • New Drugs/Dietary Supplements/Food Labeling/Misbranded

    Formulation Technology, Inc.

    2024-07-23
  • Bioresearch Monitoring Program/IRB

    Massachusetts Institute of Technology MIT

    2024-07-16

See Also (8)